CO4980869A1 - Composiciones nucleotidas analogas - Google Patents

Composiciones nucleotidas analogas

Info

Publication number
CO4980869A1
CO4980869A1 CO98042226A CO98042226A CO4980869A1 CO 4980869 A1 CO4980869 A1 CO 4980869A1 CO 98042226 A CO98042226 A CO 98042226A CO 98042226 A CO98042226 A CO 98042226A CO 4980869 A1 CO4980869 A1 CO 4980869A1
Authority
CO
Colombia
Prior art keywords
ether
mixture
ethyl acetate
butyl
butyl ether
Prior art date
Application number
CO98042226A
Other languages
English (en)
Inventor
N Arimilli Murty
Thomas T K Lee
Lawrence V Manes
John D Munger Jr
Ernest J Prisbe
M Schultze Lisa
E Kelly Daphne
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26732226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4980869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CO4980869A1 publication Critical patent/CO4980869A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Abstract

El compuesto adefovir dipivocil caraterizado por sercristalino. 2Un método que comprende la cristalización del adefovir dipivocil a partir de una solución conformada por 6-45%, de adefovir dipivocil 55-94% del solvente de cristalización donde dicho solvente se selecciona a partir del grupo conformado por: (1) una mezcla entre 1:10 v/v hasta 1:3 v/v de acetona: di-n-butil éter, (2) una mezcla entre 1:10 v/v hasta 1:3 v/v de etil acetato: di-n-propil éter, (3) una mezcla entre 1:10 v/v hasta 10:1 v/v de t-butanol: di-n-butil éter, (4) una mezcla entre 1:10 v/v hasta 1:3 v/v de cloruro de metileno: di-n-butil éter, (5) una mezcla entre 1:10 v/v hasta 10:1 v/v de dietil éter: di-n-propil éter, (6) una mezcla entre 1:10 v/v hasta 1:3 v/v de tetrahidrofurano: di-n-butil éter, (7) una mezcla entre 1:10 v/v hasta 1:3 v/v de etil acetato: di-n-butil éter, (8) una mezcla entre 1:10 v/v hasta 1:3 v/v de tetrahidropirano: di-n-butil éter, (9) una mezcla entre 1:10 v/v hasta 1:3 v/v de etil acetato: dietil éter, (10) t-butil-metil éter, (11) dietil éter, (12) di-n-butil éter, (13) t-butanol, (14) tolueno, (15) acetato de isopropilo (16) acetato de etilo, y (17) una mezcla consistente esencialmente en (A) un primer solvente de cristalización conformado por un primer éter dialquilo de la fórmula R1 -O-R2 donde R1 es un grupo alquilo que tiene 1,2, 3, 4, 5 ó 6 átomos de carbono, R2 es un grupo alquilo que tiene 2, 3, 4, 5 ó 6 átomos de carbono donde R1 y R2 son iguales o distintos, o bien ambos R1 y R2 están enlazados entre si para formar un anillo de 5-, 6-, 7-, ó 8-miembros, siempre y cuando que el éter dialquilo no sea metil-etilo éter, y (B) un segundo solvente de cristalización que se selecciona a partir del grupo conformado por (a) un segundo éter dialquilo de la fórmula R1 -O-R2 , donde el segundo éter dialquilo es distinto del primer éter dialquilo, (b) tolueno, (c) tetrahidrofurano, (d) t-butanol, (e) acetato de etilo, (f) cloruro de metileno, (g) acetato de propilo y (h) isopropanol.
CO98042226A 1997-07-25 1998-07-24 Composiciones nucleotidas analogas CO4980869A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5377197P 1997-07-25 1997-07-25
US90074597A 1997-07-25 1997-07-25

Publications (1)

Publication Number Publication Date
CO4980869A1 true CO4980869A1 (es) 2000-11-27

Family

ID=26732226

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98042226A CO4980869A1 (es) 1997-07-25 1998-07-24 Composiciones nucleotidas analogas

Country Status (24)

Country Link
EP (1) EP0996430B1 (es)
JP (4) JP3573713B2 (es)
KR (3) KR100700087B1 (es)
CN (2) CN1274700C (es)
AR (1) AR016548A1 (es)
AT (3) ATE228357T1 (es)
AU (1) AU747163B2 (es)
BR (1) BR9811552A (es)
CA (3) CA2596320C (es)
CO (1) CO4980869A1 (es)
DE (3) DE69826735T2 (es)
DK (1) DK0996430T3 (es)
ES (3) ES2229029T3 (es)
HK (5) HK1046357B (es)
ID (1) ID28006A (es)
IL (1) IL133461A (es)
IN (1) IN190037B (es)
MY (1) MY129451A (es)
NZ (1) NZ501659A (es)
PT (3) PT1256584E (es)
SI (2) SI1256584T1 (es)
TR (3) TR200200117T2 (es)
TW (1) TW584635B (es)
WO (1) WO1999004774A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596320C (en) * 1997-07-25 2008-12-23 Gilead Sciences, Inc. Nucleotide analog compositions
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
HRP20160074B1 (hr) 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
EP1504014B1 (en) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
US7417036B2 (en) 2002-11-12 2008-08-26 Tianjin Kinsly Pharmaceutical Co. Ltd. Crystal form of adefovir dipivoxil and its preparation
CN100383149C (zh) * 2002-11-12 2008-04-23 天津帝士力投资控股集团有限公司 一种新的晶状埃地双酯及其组合物
CN1303089C (zh) * 2002-11-19 2007-03-07 天津药物研究院 阿德福韦酯结晶形态及其制备方法
CN100415756C (zh) * 2003-10-14 2008-09-03 沈阳药科大学 草酸阿地福韦酯及其晶型和制备方法及用途
CN100358907C (zh) * 2004-03-31 2008-01-02 河北医科大学生物医学工程中心 一种非晶状阿德福韦酯的制备方法
CN100374118C (zh) * 2004-05-20 2008-03-12 江苏吴中中药研发有限公司 含有阿德福韦酯的滴丸剂及其制备方法
RU2006138907A (ru) 2004-06-08 2008-07-20 Метабазис Терапеутикс Синтез сложных циклических эфиров с применением кислоты льюиса
CN102228463B (zh) * 2005-06-13 2012-12-19 博瑞生物医药技术(苏州)有限公司 泰诺福韦的晶体
CN100395248C (zh) * 2006-05-26 2008-06-18 华东理工大学 一种9-(二乙氧基磷酰基甲氧基乙基)-腺嘌啉的制备方法
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101343290B (zh) * 2008-05-24 2011-02-02 广东肇庆星湖生物科技股份有限公司 一种阿德福韦酯无水结晶物的制备方法、所得的阿德福韦酯无水结晶物及其应用
WO2010005195A2 (ko) * 2008-07-07 2010-01-14 (주)아모레퍼시픽 아데포버 디피복실의 결정형 ｌ의 제조방법
KR20100031045A (ko) 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
US20110201575A1 (en) * 2008-09-17 2011-08-18 Cj Cheiljedang Corporation Stabilized solid dispersion of adefovir dipivoxil and preparation method thereof
KR20100032803A (ko) * 2008-09-18 2010-03-26 씨제이제일제당 (주) 아데포비어디피복실의 개선된 제조방법
KR20100061401A (ko) * 2008-11-28 2010-06-07 (주)아모레퍼시픽 아데포버 디피복실의 결정형, 그 제조방법 및 그를 포함하는 약제학적 조성물
US9169257B2 (en) 2009-03-26 2015-10-27 Daewoong Pharmaceutical Co., Ltd. Crystal forms of adefovir dipivoxil and processes for preparing the same
KR20100113302A (ko) * 2009-04-13 2010-10-21 한미홀딩스 주식회사 결정형 아데포비어 디피복실의 제조방법 및 이에 사용되는 아데포비어 디피복실 부탄올레이트
KR101528754B1 (ko) * 2009-04-14 2015-06-17 중앙대학교 산학협력단 신규한 복합결정형의 화합물, 그 제조방법 및 이를 포함하는 약제학적 조성물
KR100971486B1 (ko) * 2009-06-11 2010-07-21 주식회사 셀트리온화학연구소 아데포비어 다이피복실 말론산염 및 이를 포함하는 약제학적 조성물
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
WO2011016611A2 (ko) * 2009-08-03 2011-02-10 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 ｂ형 간염의 예방 또는 치료용 조성물
KR101129575B1 (ko) * 2009-09-02 2012-03-28 경희대학교 산학협력단 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
KR101048024B1 (ko) * 2009-10-09 2011-07-13 주식회사 삼오제약 9-(2-포스포닐메톡시에틸)아데닌, 아데포비아 디피복실 및 무정형 아데포비아 디피복실의 제조방법
EP2343056A1 (en) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
WO2012032541A1 (en) * 2010-09-06 2012-03-15 Matrix Laboratories Ltd "adefovir dipivoxil pseudopolymorph"
WO2012062835A1 (en) 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
CN102250146A (zh) * 2011-05-27 2011-11-23 扬州三友合成化工有限公司 抗乙肝药物阿德福韦的一种合成方法
KR101357687B1 (ko) * 2011-11-25 2014-02-05 숭실대학교산학협력단 고분자 첨가제를 이용한 아데포비어 디피복실 복합체의 결정입자 제어방법 및 이의 응용
KR101258678B1 (ko) 2012-02-29 2013-04-26 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 β형 간염의 예방 또는 치료용 조성물
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN102816184B (zh) * 2012-09-07 2015-11-18 山东大学 (2-(2-氧基-4-硫代嘧啶)乙氧基)甲基膦酸酯类衍生物及其制备与应用
CN103709198A (zh) * 2012-09-28 2014-04-09 江苏天士力帝益药业有限公司 一种阿德福韦酯的结晶方法
CN103333208B (zh) * 2013-06-04 2016-05-11 广州晶莱医药科技有限公司 阿德福韦酯马来酸盐及其制备方法和组合物
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
EP3372227A1 (en) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablet formulation of adefovir dipivoxil
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
CA2126601A1 (en) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
CA2596320C (en) * 1997-07-25 2008-12-23 Gilead Sciences, Inc. Nucleotide analog compositions

Also Published As

Publication number Publication date
KR20010014284A (ko) 2001-02-26
ES2187991T3 (es) 2003-06-16
IL133461A (en) 2005-05-17
WO1999004774A2 (en) 1999-02-04
CA2298057C (en) 2008-11-18
PT1256584E (pt) 2004-12-31
JP3573713B2 (ja) 2004-10-06
CN1216062C (zh) 2005-08-24
DE69809749T2 (de) 2003-09-11
HK1051693A1 (en) 2003-08-15
CA2596497A1 (en) 1999-02-04
CA2596497C (en) 2008-12-23
ATE277937T1 (de) 2004-10-15
KR100618663B1 (ko) 2006-09-08
AR016548A1 (es) 2001-07-25
KR20060038363A (ko) 2006-05-03
DE69826735T2 (de) 2005-10-06
CN1251592A (zh) 2000-04-26
CA2596320C (en) 2008-12-23
HK1046357A1 (en) 2003-01-10
JP2001512712A (ja) 2001-08-28
ES2229030T3 (es) 2005-04-16
HK1046357B (zh) 2007-08-24
CN1274700C (zh) 2006-09-13
PT1256585E (pt) 2005-01-31
WO1999004774A3 (en) 1999-04-15
ATE228357T1 (de) 2002-12-15
IN190037B (es) 2003-05-31
SI1256585T1 (en) 2005-02-28
MY129451A (en) 2007-04-30
TR200200117T2 (tr) 2002-06-21
NZ501659A (en) 2004-12-24
ATE277936T1 (de) 2004-10-15
KR20060038364A (ko) 2006-05-03
JP4452034B2 (ja) 2010-04-21
CA2298057A1 (en) 1999-02-04
HK1051694A1 (en) 2003-08-15
EP0996430B1 (en) 2002-11-27
TR200000224T2 (tr) 2000-07-21
AU747163B2 (en) 2002-05-09
PT996430E (pt) 2003-03-31
DE69826734T2 (de) 2005-10-06
JP2009263389A (ja) 2009-11-12
CA2596320A1 (en) 1999-02-04
HK1091212A1 (en) 2007-01-12
IL133461A0 (en) 2001-04-30
DE69809749D1 (de) 2003-01-09
ES2229029T3 (es) 2005-04-16
EP0996430A2 (en) 2000-05-03
TR200200137T2 (tr) 2002-09-23
DE69826734D1 (de) 2004-11-04
CN1347695A (zh) 2002-05-08
HK1091211A1 (en) 2007-01-12
AU8660998A (en) 1999-02-16
DK0996430T3 (da) 2003-03-10
JP2005306879A (ja) 2005-11-04
KR100700087B1 (ko) 2007-03-28
BR9811552A (pt) 2000-08-29
KR100700089B1 (ko) 2007-03-28
DE69826735D1 (de) 2004-11-04
TW584635B (en) 2004-04-21
ID28006A (id) 2001-05-03
JP2003342283A (ja) 2003-12-03
SI1256584T1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
CO4980869A1 (es) Composiciones nucleotidas analogas
ATE215078T1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
KR960703398A (ko) 피페리딘 유도체 및 그의 제조 방법(Piperidine Derivatives and Process for Their Production)
ZA944884B (en) Derivatives of valproic acid amides and 2-valproenoic acid amides method of making and use thereof as anticonvulsant agent
AU3313784A (en) Verfahren zur herstellung von oligonucleotiden
ATE46696T1 (de) 1- und 1,1-disubstituierte, 6-substituierte, 2carbamimidoyl-1-carbadethiapen-2-em-3carbons|uren, verfahren zur herstellung und diese enthaltende antibiotische zusammensetzung.
KR880000399A (ko) 융합된 트리사이클릭 락탐
CO4870725A1 (es) Composiciones limpiadoras en microemulsion a base de tensio- activos , para todo proposito
MY119242A (en) Method for enhancing the efficacy of agricultural chemical,enhancer composition for agricultural chemical and agricultural chemical composition
ATE270301T1 (de) Verfahren zur herstellung von modifizierten p- chiralen nucleotid-analoga
HUP0203117A2 (hu) Semleges kationos lipid nukleinsav és hatóanyag szállítására
KR910000947A (ko) 금속 안료 조성물
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
EP0295304A4 (en) SYNTHETIC TRACTION FLUID.
MX172211B (es) Composicion de olefina polisulfurada y el procedimiento para su preparacion
DE69616719D1 (de) Verfahren zur herstellung von taxol und seiner derivate
KR870003107A (ko) 키산틴 유도체의 제조방법
ATE173922T1 (de) 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung
RU2003102446A (ru) Новые полициклические ксантоны и их применение
CA2308315A1 (en) N,n'-bis(sulfonyl)hydrazines useful as antineoplastic agents
EP0240890A3 (en) Prostacyclin (pgi2) analogues
KR930702378A (ko) 17-β-에스트라디올 유도체, 이것의 제조방법 및 이 화합물을 함유하는 약제
KR880013938A (ko) 활성 화합물들
MY126669A (en) Method and compositions for inhibiting the scent tracking ability of biting miges
KR870007188A (ko) 경구 활성 포스포닐히드록시아실 프롤린 및 그의 제조 방법